medigraphic.com
Colegio de Medicina Interna de México.

2017, Number 5

<< Back Next >>

Med Int Mex 2017; 33 (5)

Prevalence of Malassezia spp in type 2 diabetes mellitus according to glycemic control

Bello-Hernández Y, García-Valdés L, Cruz S, Pérez D, Vega D, Torres E, Fernández R, Arenas R

Language: Spanish
References: 23
Page: 612-617
PDF size: 507.36 Kb.


ABSTRACT

Background: Malassezia spp is a saprophyte of the skin, related to diverse cutaneous affections, and has been reported a high frequency in patients with immunosuppression.
Objetive: To determine the prevalence of Malassezia spp in individuals with type 2 diabetes mellitus according to glycemic control.
Material and Method: An open, observational, descriptive and cross-sectional study was performed in volunteer patients who participated in the 24th National March of the Patient with Diabetes in Mexico City on October 15, 2016; where preprandial capillary glycemia and glycosylated hemoglobin were taken. We took a scraping of the malar region skin to find Malassezia spp, smears stained with methylene blue.
Results: A total of 49 patients with type 2 diabetes mellitus were included; there were a predominance of 31 patients without glycemic control (67%) in comparison with 16 controlled patients (33%). Smears with low yeast (+) were present in 21 (59%) uncontrolled patients and in 7 (41%) controlled patients; smears with a moderate amount of yeast (++) were present in 7 (74%) uncontrolled patients and in 5 (26%) controlled patients; smears with abundant yeasts were present in 7 (63%) uncontrolled patients and in 2 (37%) controlled patients.
Conclusion: In our study the prevalence of Malassezia spp in patients with type 2 diabetes mellitus was of 100%, with a lower number of yeasts in patients with adequate glycemic control; this can indicate that the possibility of presenting this yeast increases with bad glycemic control and probably denotes the degree of immunosuppression in these patients.


REFERENCES

  1. Zaballos DP. Manifestaciones cutáneas de la diabetes. Rev Med Integ Junio 2001;38(1):38-42.

  2. Hernández-Ávila M, Gutiérrez JP, Reynoso-Noverón N. Diabetes mellitus en México. El estado de la epidemia. Rev Salud Publica Mex 2013;55 supl 2:S129-S136.

  3. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004;88(4):787-835.

  4. Donnelly R, Emslie-Smith AM, Gardner I, Morris A. ABC of vascular disease: Vascular complications of diabetes. BMJ 2000;320(7245):1062-1066.

  5. Pereira O, Palay M, Rodríguez A, Neyra R, Chia M. Hemoglobina glucosilada en pacientes con diabetes mellitus. MEDISAN 2015;19(4):555.

  6. García FJ. Utilización de la hemoglobina glucosilada para el diagnóstico de diabetes. Cad Aten Primaria 2009;16:228- 229.

  7. Davidson MB, Schriger DL, Peters AL, Lorber B. Relationship between fasting plasma glucose and glycosylated hemoglobin. JAMA 1999;281:1203-1210.

  8. Múnera-Jaramillo MI, Restrepo-Lozada MA, Gómez-Bahamon LM, Mesa-Suárez D, Ramírez-Puerta BS. Hemoglobina glicosilada A1c vs glucemia plasmática en ayunas de pacientes ambulatorios de un laboratorio médico. Rev Salud Pub 2011;13(6):980-989.

  9. Mediavilla-Bravo JJ. Complicaciones de la diabetes mellitus. Diagnóstico y tratamiento. SEMERGEN 2001;27:132-145.

  10. Pérez MI, Kohn SR. Cutaneous manifestations of diabetes mellitus. J Am Acad Dermatol 1994;30:519-531.

  11. Timshina DK, Thappa DM, Agrawal A. A clinical study of dermatoses in diabetes to establish its markers. Indian J Dermatol 2012;57:20-25.

  12. Bermúdez V, Bermúdez F, Arraiz N, Leal E, Linares S, Mengual E. Biología molecular de los transportadores de glucosa: clasificación, estructura y distribución. Archivos Venezolanos de Farmacología y Terapéutica 2007;26:76-86.

  13. Hernández-Hernández F. El género Malassezia y patologías asociadas. Actualidades en Micología Médica. México: Fac Med UNAM 2004;143-157.

  14. Bergbrant IM, Faergemann J, Voog E, Löwhagen GB. Pityrosporum ovale and seborrhoeic dermatitis in HIVseropositive and HIV-seronegative men. Quantitative cultures and serological studies. J Europ Acad Dermatol Venereol 1996;6:147-151.

  15. American Diabetes Association. Diabetes Care 2017;40(Suppl. 1):S48-S56.

  16. Roses M, Rosas-Guzmán J. Guías ALAD de diagnóstico, control y tratamiento de la Diabetes Mellitus Tipo 2. Organización Mundial de la Salud, 2006;14:56-59.

  17. Calvo-Vázquez I, Sánchez-Luna O, Yáñez-Sosa AL. Prevalencia de enfermedad renal crónica no diagnosticada en pacientes con diabetes mellitus tipo 2 en atención primaria a la salud. Med Int Méx 2015;31:41-49.

  18. Vázquez Aguirre MV, Rojas J, Bermúdez V. Comportamiento epidemiológico del hipotiroidismo en pacientes con diabetes mellitus tipo 2 en la ciudad de Loja-Ecuador. Revista Latinoamericana de Hipertensión 2013;8(4):95-102.

  19. Gutiérrez JP, Rivera-Dommarco J, Shamah-Levy T, Villalpando-Hernández S y col. Encuesta Nacional de Salud y Nutrición 2012. Resultados Nacionales. Cuernavaca, México: Instituto Nacional de Salud Pública (MX) 2012;1:108-112.

  20. Tello-Ibáñez OO, Fabián-San Miguel G, Arenas R, Guevara- Cervantes JF, Fernández R. Dermatitis seborreica y Malassezia. Relación en pacientes con diabetes mellitus tipo 2. Med Int Méx 2016:32(2):185-189.

  21. Torres E, Arenas R, Atoche-Diéguez C. Infecciones causadas por el género Malassezia. Med Cutan Iber Lat Am 2008;36:265-284.

  22. Crespo-Erchiga V, Delgado-Florencio V. Malassezia species in skin diseases. Curr Opin Infect Dis 2002;15:133-142.

  23. Daoud AK, Tayyar MA, Fouda IM, Harfeil NA. Effects of diabetes mellitus vs in vitro hyperglycemia on select immune cell functions. J Immunotoxicol 2009;6:36-41.




2020     |     www.medigraphic.com